Evidence map›Paper›PMID 40950472›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Baseline epigenetics as a biomarker of mepolizumab response in severe asthma.

Hongmei Zhang, Xin Jin, Hasan Arshad, Ramesh J Kurukulaaratchy

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Hongmei ZhangDivision of Epidemiology, Biostatistics, Environmental Health, School of Public Health, University of Memphis, Memphis, TN, USA.
Xin JinDivision of Epidemiology, Biostatistics, Environmental Health, School of Public Health, University of Memphis, Memphis, TN, USA.
Hasan ArshadThe David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Isle of Wight, UK.
Ramesh J KurukulaaratchyThe David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Isle of Wight, UK.

Funding

Clusters of Epigenetic Networks at Birth and Asthma Incidence in ChildrenR21AI175891 · NIAID · UNIVERSITY OF MEMPHIS · PI ZHANG, HONGMEI · 2023 to 2024
$380k
NIAID NIH HHS R21 AI175891
6 · The paper itself

Abstract

Biologic treatment options have expanded considerably for severe asthma, transforming patient management, but only ~70% of patients respond to the treatment following standard criteria. This preliminary study utilized data collected in the Wessex AsThma CoHort of difficult asthma (WATCH) study. DNAm was measured in n=15 severe asthma patients at baseline, i.e., before mepolizumab (MEPO), an interleukin-5 receptor antagonist, was administered and the response to MEPO was analyzed. We aimed to assess the potential of DNA methylation as a feasible biomarker to predict responses to MEPO among severe asthma patients. Our preliminary findings suggested that pre-biologic DNA methylation as a predictor of a patient's response status may outperform pre-biologic blood eosinophils cell counts.

Indexed as

Biologic drugsDNA methylationMarkersPredictionSevere asthma

Identifiers

PMID40950472
PMCPMC12425039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.